Fact Sheet for Patients, Parents And Caregivers Emergency Use Authorization (EUA) of EVUSHELD™ (tixagevimab co-packaged with cilgavimab) for Coronavirus Disease 2019 (COVID-19). More about Evusheld (cilgavimab / tixagevimab) Check interactions ...
Issuance of the EUA was based on the results of an unpublished double-blind trial (PROVENT; summarized in the FDA Fact Sheet) in 5172 adults who were not vaccinated against COVID-19 and at elevated risk because of their age (≥60 years), a comorbidity (eg, obesity, COPD, immune comprom...
12 years or older who have a moderately to severely compromised immune system because of a medical condition such as cancer or immunosuppressive treatments, or they’ve had a severe reaction to any of the COVID-19 vaccines or their components, according to its Emergency Use Authorization (EUA)...
In individuals who have received a COVID-19 vaccine, EVUSHELD should be administered at least two weeks after vaccination Please see theFact Sheet for Healthcare ProvidersandFact Sheet for Patients, Parents and Caregivers. Under the EUA, all serious adverse events and medicat...
12 years or older who have a moderately to severely compromised immune system because of a medical condition such as cancer or immunosuppressive treatments, or they’ve had a severe reaction to any of the COVID-19 vaccines or their components, according to its Emergency Use Authorization ...